MedTrace Logo

Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer

NCT05531981 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2022-10-13

No results posted yet for this study

Summary

In this study, a large-scale cohort of cervical cancer patients was established in multiple centers. Minimal residual disease(MRD) was assessed by ddPCR detection of HPV E7 gene ctDNA to assess tumor burden and predict the risk of disease recurrence, so as to provide new biomarkers for precise treatment of cervical cancer patients. The study continued until 36 months after the end of treatment.

Conditions

  • Uterine Cervical Neoplasms

Interventions

OTHER

detect HPV E7 ctDNA

Peripheral blood was collected from the patients, and the copy number of HPV E7 gene in ctDNA was accurately detected by ddPCR

Sponsors & Collaborators

  • Beijing Obstetrics and Gynecology Hospital

    collaborator OTHER

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Precision Scientific (Beijing) Co., Ltd

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2024-09-01
Completion
2025-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05531981 on ClinicalTrials.gov